Grace Therapeutics Inc. Financials
GRCE
All currency values in $ millions unless otherwise noted
Scroll
| Income Statement | MAR 2026 ~1.4:1 split | MAR 2025 | MAR 2024 | MAR 2023 | MAR 2022 ~2.5:1 split |
|---|---|---|---|---|---|
| Revenues | |||||
| Revenue | – | – | – | – | $100 |
| Cost of Revenue | – | – | – | – | $0 |
| Gross Profit | – | – | – | – | $100 |
| Operating Expenses | |||||
| Selling & Marketing | – | – | $0 | $1 | $1 |
| General & Administrative | $9 | $7 | $7 | $8 | $9 |
| Research & Development | $2 | $10 | $5 | $10 | $6 |
| Total Operating Expenses | – | – | $12 | $18 | $15 |
| Operating Income | -$11 | -$17 | -$13 | -$52 | -$16 |
| Non-Operating | |||||
| Net Interest Expense | $1 | $1 | $1 | $0 | $0 |
| Other Non-Operating Income (Expense) | $1 | $3 | -$3 | -$0 | $5 |
| EBT (Earnings Before Tax) | -$9 | -$13 | -$15 | -$52 | -$10 |
| Income Tax Expense | -$2 | -$3 | -$2 | -$10 | -$1 |
| Net Income | |||||
| Net Income | -$8 | -$10 | -$13 | -$42 | -$10 |
| Per Share Data | |||||
| Revenue Per Share | – | – | – | – | $16.29 |
| EPS (Basic) | -$0.47 | -$0.79 | -$1.35 | -$5.71 | -$1.62 |
| EPS (Diluted) | -$0.47 | -$0.79 | -$1.35 | -$5.71 | -$1.62 |
| Weighted Avg Shares (Basic) | 16.5M | 12.1M | 9.5M | 44.6M | 36.8M |
| Weighted Avg Shares (Diluted) | 16.5M | 12.1M | 9.5M | 44.6M | 36.8M |
| Shares Outstanding | 16.5M | 12.1M | 9.5M | 7.4M | 6.1M |
Grace Therapeutics (GRCE) financials: revenue, profit and margins
Grace Therapeutics (GRCE) generated about n/a in revenue and -$21 million in net income over the trailing twelve months, growing at roughly 50,920.4% a year. Figures are from SEC filings; this is analysis, not investment advice.
Frequently asked
Is Grace Therapeutics profitable?+
Grace Therapeutics reported about -$21 million in net loss over the trailing twelve months. Net income is the bottom line after all costs, interest and taxes. Compare it to free cash flow on this tab, since reported profit and actual cash generated can diverge.
How fast is Grace Therapeutics growing?+
Grace Therapeutics's revenue has compounded at roughly 50,920.4% a year over the past five years. Growth only creates value when it is profitable and cash-generative, so read this rate alongside GRCE's margins and free cash flow. This is analysis from SEC filings, not investment advice.
SourceFinancial statements computed from the 10-Q filed 11 Nov 2026, covering the period ending 30 Sept 2026, as reported to the SEC. Data last refreshed 12 Nov 2026. How this is calculated.
Fiscal year ends Mar.
Peers
Pharmaceutical Preparations · Pick stocks to compare with GRCE
Spot a number that looks wrong? Check it in GRCE's SEC filings or
Download this analysis as a PDF (Pro)
Data sourced from SEC EDGAR filings and third-party price providers. Scores, valuations, and metrics are algorithmic estimates. This is not investment advice. See our Terms and Methodology.
Keep analysing GRCE
A free account gives you 10 stocks a day, a watchlist and price alerts.
Already have an account?
Or come back tomorrow. Stocks on your watchlist are always free to view.